How should we balance individual and population benefits of statins for preventing cardiovascular disease?

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.c6244 (Published 26 January 2011)
Cite this as: BMJ 2011;342:c6244

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Aroon D Hingorani, professor of genetic epidemiology1,
  2. Harry Hemingway, professor of clinical epidemiology2
  1. 1Genetic Epidemiology Group, Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK
  2. 2Clinical Epidemiology Group, Department of Epidemiology and Public Health, University College London, UK
  1. Correspondence to: A D Hingorani a.hingorani{at}ucl.ac.uk
  • Accepted 18 October 2010

US and UK groups revising recommendations on primary prevention of cardiovascular disease will have to decide whether to concentrate on high risk individuals or the whole population. Aroon Hingorani and Harry Hemingway argue that the evidence favours a population approach

Guideline groups in the United Kingdom and the United States are reviewing recommendations for the primary prevention of cardiovascular disease. At their disposal will be good quality evidence on the quantitative relation between the major risk factors and the probability of a first cardiovascular event1; the extent of the current population exposure to risk factors2 3; and the safety and efficacy of drugs to lower blood pressure and cholesterol concentrations.4 5 The decisions of these expert groups will have far reaching consequences for the millions of adults in both countries, where cardiovascular disease is the biggest cause of mortality and morbidity; around half of men and a third of women have a cardiovascular event during their life.6

There are new drivers to modify the existing guidance (table 1; box), and two extreme positions could be envisaged (table 2). The first is to redouble efforts to identify high risk individuals by enhancing currently used risk prediction tools with new information from blood biomarkers or non-invasive vascular imaging; to treat those at high risk with newer more expensive statins that achieve the greatest cholesterol reduction; and to tailor treatment for each individual to achieve target cholesterol levels. The interest in C reactive protein as a new biomarker of cardiovascular risk7 and the recent US Food and Drug Administration licence extension of the patent for rosuvastatin, with C reactive protein as a companion test, suggests that the US could follow this course. The diametric alternative is to use generic versions of the older …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL